Search | IOVS | ARVO Journals

Showing 1 – 20 of 130

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2025

Differentiating treatment episodes and gaps in eyes with diabetic macular edema

Yohei Hashimoto; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):2384.

ARVO Annual Meeting Abstract June 2025

Regulating RPE Cell Dedifferentiation for the Treatment of Subretinal Fibrosis in Neovascular Age-related Macular Degeneration

Jiawen Fan; Zijia Zhao; Gezhi Xu; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):3758.

ARVO Annual Meeting Abstract June 2025

Influence of Inflammation on the Efficacy of Lipid Nanoparticle-Mediated Retinal Drug Delivery

Shaoxue Zeng; Jiaxuan Zhao; Jialing Zhang; Ting Zhang; Michelle Yam; Sora Lee; Mark C Gillies; Ling Zhu

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):5986.

ARVO Annual Meeting Abstract June 2025

Unveiling Distinct Coding and Non-Coding RNA Expression in Macular vs. Mid-peripheral Retina

Jialing Zhang; Ting Zhang; Yue Zeng; Shaoxue Zeng; Meidong Zhu; Ling Zhu; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):1192.

ARVO Annual Meeting Abstract June 2025

Uncovering Metabolic Specialization in the Human Macula: Insights from the Macula-on-a-Chip (MoaC) System for the pathogenesis of Macular Telangiectasia type 2 (MacTel)

Ling Zhu; Ting Zhang; Yue Zeng; Jialing Zhang; Sora Lee; Jianhai Du; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):3241.

ARVO Annual Meeting Abstract June 2025

Real World Outcomes of Faricimab for wet Age-Related Macular Degeneration: High quality data from an Australian Registry

Mark C Gillies; Adrian Robert Hunt; Yohei Hashimoto

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):3106.

ARVO Annual Meeting Abstract June 2025

Deciphering Genetic Influencers of Subretinal Fibrosis in wet AMD: A Machine Learning Approach to RNA-seq Analysis in JR5558 Mice

Ting Zhang; Kuan Yan; Yue Zeng; Dai Shi; Dmytro Matsypura; Mark C Gillies; Ling Zhu; Junbin Gao

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):4174.

ARVO Annual Meeting Abstract June 2025

Role of Alanine Transaminase in Retinal Metabolic Homeostasis: Potential therapeutic target in retinal diseases

QIN CHEN; Ting Zhang; Michelle Yam; Sora Lee; jingwen zeng; Meidong Zhu; Ming Zhang; Fang Lu; Jianhai Du; Ling Zhu; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):4063.

ARVO Annual Meeting Abstract June 2024

Detection of outlying practitioners for the treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor agents

Yohei Hashimoto; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1364.

ARVO Annual Meeting Abstract June 2024

Long Term Outcomes for Neovascular Age-related Macular Degeneration in a Frugal Country: The Netherlands

Haras Mhmud; Odette M Tigchelaar-Besling; Jeroen Vermeulen; Frank D Verbraak; Daniel Barthelmes; Mark C Gillies; Dirk Ponsioen; Caroline C W Klaver

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2118.

ARVO Annual Meeting Abstract June 2024

Six-Month Outcomes of Switching to Faricimab in Eyes with Neovascular Age-Related Macular Degeneration

Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):256.

ARVO Annual Meeting Abstract June 2024

Exploring the Effects of 1-Deoxysphingolipids on Human Macula: Insights from the Macula-on-a-Chip (MoaC) System

Yue Zeng; Ting Zhang; Michelle Yam; So-Ra Lee; Jialing Zhang; Shaoxue Zeng; Yingying Chen; Meidong Zhu; Meixia Zhang; Kevin Thomas Eade; Ling Zhu; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1697.

ARVO Annual Meeting Abstract June 2024

Sacrificing Adaptability for Functionality: The Ivory Tower of Macular Müller Cells

Ling Zhu; Ting Zhang; Kaiyu Jin; Shaoxue Zeng; Penghui Yang; Meidong Zhu; Jialing Zhang; Yingying Chen; So-Ra Lee; Michelle Yam; Yue Zeng; Andrew Chang; Jianhai Du; Xiaohui Fan; Mark C Gillies; Xiaoyan Lu

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1679.

ARVO Annual Meeting Abstract June 2024

Linking multimodal image-linkage with the FRB! registry to enhance its globally impactful research potential – the beginning of “FRB! 2.0”.

Ash Kras; Mark C Gillies; Jennifer Arnold; Daniel Barthelmes; Hemal Mehta

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5631.

ARVO Annual Meeting Abstract June 2024

A double-masked, Placebo-Controlled, Phase 1b/2a Study of EXN407 Eye Drops in Patients with Mild Center Involving Diabetic Macular Edema (DME)

loic Cm lhuillier; Hemal Mehta; Jagjit Gilhotra; Fred Chen; Sanjeewa Wickremasinghe; Wilson Heriot; Peter Davies; Lily Ooi; Jennifer Arnold; Rohan Merani; Mike Taylor; David O Bates; Samantha Fraser-Bell; Mark C Gillies; Mario G Fsadni; Andrew Chang

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6248.

ARVO Annual Meeting Abstract June 2024

Differential Roles of 2-Tail and 3-Tail Phospholipids in LNPs for RNA Delivery to the Human Retina

Shaoxue Zeng; Kaiyu Jin; Ting Zhang; Jialing Zhang; Xiaohui Fan; Wojciech Chrzanowski; Mark C Gillies; Ling Zhu

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6166.

ARVO Annual Meeting Abstract June 2023

Six-month Outcomes of Brolucizumab in Routine Clinical Practice: Data from the Fight Retinal Blindness! Registry

Mark Gillies; trung dang; Vuong Nguyen; Alessandro Invernizzi; Francesco Romano; Mariano Cozzi; Jennifer Arnold; james wong; hemal mehta; samantha Fraser-Bell; Richard Barry; Daniel Barthelmes; Alan Luckie

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):466.

ARVO Annual Meeting Abstract June 2023

Real-world unmet needs in the management of poorly responsive neovascular age-related macular degeneration in Europe: data from the FRB! Registry

Pierre-Henry GABRIELLE; Clotilde Boudousq; vuong nguyen; Javier Zarranz-Ventura; Alain Marie Bron; Daniel Barthelmes; Mark Gillies; Catherine Creuzot-Garcher

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2199.

ARVO Annual Meeting Abstract June 2023

Metabolic alterations in the JR5558 mouse model of subretinal fibrosis

Yue Zeng; Ting Zhang; Ling Zhu; So-Ra Lee; Shaoxue Zeng; Michelle Yam; Jianhai Du; Mark Gillies

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2969.

ARVO Annual Meeting Abstract June 2023

Single-cell RNA sequencing-based comparison of Pfizer and Moderna lipid nanoparticles in delivering RNA to the human retina

Shaoxue Zeng; Kaiyu Jin; Ting Zhang; Jialing Zhang; Xiaohui Fan; wojciech chrzanowski; Mark Gillies; Ling Zhu

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2600.

1 2 3 4 5

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Filters

Specify Date Range

Differentiating treatment episodes and gaps in eyes with diabetic macular edema

Regulating RPE Cell Dedifferentiation for the Treatment of Subretinal Fibrosis in Neovascular Age-related Macular Degeneration

Influence of Inflammation on the Efficacy of Lipid Nanoparticle-Mediated Retinal Drug Delivery

Unveiling Distinct Coding and Non-Coding RNA Expression in Macular vs. Mid-peripheral Retina

Uncovering Metabolic Specialization in the Human Macula: Insights from the Macula-on-a-Chip (MoaC) System for the pathogenesis of Macular Telangiectasia type 2 (MacTel)

Real World Outcomes of Faricimab for wet Age-Related Macular Degeneration: High quality data from an Australian Registry

Deciphering Genetic Influencers of Subretinal Fibrosis in wet AMD: A Machine Learning Approach to RNA-seq Analysis in JR5558 Mice

Role of Alanine Transaminase in Retinal Metabolic Homeostasis: Potential therapeutic target in retinal diseases

Detection of outlying practitioners for the treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor agents

Long Term Outcomes for Neovascular Age-related Macular Degeneration in a Frugal Country: The Netherlands

Six-Month Outcomes of Switching to Faricimab in Eyes with Neovascular Age-Related Macular Degeneration

Exploring the Effects of 1-Deoxysphingolipids on Human Macula: Insights from the Macula-on-a-Chip (MoaC) System

Sacrificing Adaptability for Functionality: The Ivory Tower of Macular Müller Cells

Linking multimodal image-linkage with the FRB! registry to enhance its globally impactful research potential – the beginning of “FRB! 2.0”.

A double-masked, Placebo-Controlled, Phase 1b/2a Study of EXN407 Eye Drops in Patients with Mild Center Involving Diabetic Macular Edema (DME)

Differential Roles of 2-Tail and 3-Tail Phospholipids in LNPs for RNA Delivery to the Human Retina

Six-month Outcomes of Brolucizumab in Routine Clinical Practice: Data from the Fight Retinal Blindness! Registry

Real-world unmet needs in the management of poorly responsive neovascular age-related macular degeneration in Europe: data from the FRB! Registry

Metabolic alterations in the JR5558 mouse model of subretinal fibrosis

Single-cell RNA sequencing-based comparison of Pfizer and Moderna lipid nanoparticles in delivering RNA to the human retina

To View More...

You must be signed into an individual account to use this feature.